ACTG1 and cancer: Liu et al. conformed that lncRNA Actin Gamma 1 Pseudogene (AGPG) may be regarded as a potential biomarker and cancer therapeutic target and that inhibiting AGPG dramatically impaired glycolysis activity and cell proliferation in esophageal squamous cell carcinoma (ESCC) (44).